Your browser doesn't support javascript.
Ublituximab (Briumvi) for Relapsing Multiple Sclerosis
Medical Letter on Drugs and Therapeutics ; 2023(1671):36-38, 2023.
Article in English | EMBASE | ID: covidwho-2291372
Keywords
chill/si [Side Effect]; clinical study; dose response; drug contraindication; drug cost; drug efficacy; drug fatality/si [Side Effect]; drug fever/si [Side Effect]; drug formulation; drug half life; drug indication; drug metabolism; drug potentiation; drug safety; fatigue/si [Side Effect]; flu like syndrome/si [Side Effect]; Food and Drug Administration; headache/si [Side Effect]; hepatitis B/si [Side Effect]; herpes simplex/si [Side Effect]; hospitalization; human; hypersensitivity; immunoglobulin blood level; infusion related reaction/si [Side Effect]; insomnia/si [Side Effect]; lactation; letter; limb pain/si [Side Effect]; lower respiratory tract infection/si [Side Effect]; maintenance drug dose; multiple sclerosis/dm [Disease Management]; multiple sclerosis/dt [Drug Therapy]; neutrophil; patient monitoring; practice guideline; pregnancy; premedication; progressive multifocal leukoencephalopathy; side effect/si [Side Effect]; standardization; treatment duration; upper respiratory tract infection/si [Side Effect]; virus reactivation; antihistaminic agent; beta1a interferon; cladribine; corticosteroid; dimethyl fumarate; fingolimod; glatiramer; immunoglobulin M/ec [Endogenous Compound]; live vaccine/it [Drug Interaction]; natalizumab/dt [Drug Therapy]; ocrelizumab/dt [Drug Therapy]; ofatumumab/dt [Drug Therapy]; ozanimod; rituximab/dt [Drug Therapy]; SARS-CoV-2 vaccine; siponimod; teriflunomide/ct [Clinical Trial]; teriflunomide/cm [Drug Comparison]; teriflunomide/dt [Drug Therapy]; ublituximab/ae [Adverse Drug Reaction]; ublituximab/ct [Clinical Trial]; ublituximab/cm [Drug Comparison]; ublituximab/do [Drug Dose]; ublituximab/it [Drug Interaction]; ublituximab/dt [Drug Therapy]; ublituximab/pr [Pharmaceutics]; ublituximab/pe [Pharmacoeconomics]; ublituximab/pk [Pharmacokinetics]; ublituximab/pd [Pharmacology]; relapsing multiple sclerosis/dm [Disease Management]; relapsing multiple sclerosis/dt [Drug Therapy]; briumvi
Search on Google
Collection: Databases of international organizations Database: EMBASE Language: English Journal: Medical Letter on Drugs and Therapeutics Year: 2023 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS

Search on Google
Collection: Databases of international organizations Database: EMBASE Language: English Journal: Medical Letter on Drugs and Therapeutics Year: 2023 Document Type: Article